S 364735

Drug Profile

S 364735

Alternative Names: GSK 364735; S-364735

Latest Information Update: 26 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shionogi - GlaxoSmithKline (JV)
  • Class Antiretrovirals
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 30 Jul 2007 Discontinued - Phase-II for HIV infections treatment in USA (PO)
  • 12 Mar 2007 Clinical data presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI-2007) added to the adverse events and pharmacokinetics section
  • 31 Oct 2006 Phase-II clinical trials in HIV infections treatment in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top